BioPharmaTrend
Latest News
All Topics
  • Artificial Intelligence
  • NeuroTech
  • Premium Content
  • Knowledge Center
Interviews
Companies
  • Company Directory
  • Sponsored Case Studies
  • Create Company Profile
More
  • About Us
  • Our Team
  • Advisory Board
  • Citations and Press Coverage
  • Partner Events Calendar
  • Advertise with Us
  • Write for Us
Subscribe
Login/Join

  Latest News

Aqemia Raises €60m in Series A Funding to Advance AI-Driven Drug Discovery

by News Team   •   Feb. 2, 2024  

Disclaimer: All opinions expressed by Contributors are their own and do not represent those of their employers, or BiopharmaTrend.com.
Contributors are fully responsible for assuring they own any required copyright for any content they submit to BiopharmaTrend.com. This website and its owners shall not be liable for neither information and content submitted for publication by Contributors, nor its accuracy.

# Startups & Deals   
Share:   Share in LinkedIn  Share in Bluesky  Share in Reddit  Share in Hacker News  Share in X  Share in Facebook  Send by email

Aqemia, a Paris-based biotech startup, raised an additional €30 million in a Series A funding extension, totaling €60 million in equity for this round. This financial milestone will fuel the company's innovative approach to drug discovery, leveraging generative artificial intelligence (AI) and quantum-inspired algorithms to expedite the development of new drug molecules.

#advertisement
AI in Drug Discovery Report 2025

The company's funding journey began with an initial €30 million raised in 2022, led by Eurazeo and Bpifrance, with Elaia also participating. Wendel Growth boosted the latest funding extension, with continued investment from Aqemia's initial backers. This financial backing underscores the potential of Aqemia's technology to transform the drug discovery process, which is traditionally a time-consuming and expensive endeavor.

Aqemia's proprietary technology aims to accelerate the identification and design of molecular candidates for drug development. By integrating generative AI with quantum-inspired algorithms, Aqemia can rapidly generate and evaluate millions of potential drug molecules. This approach can significantly shorten the timeline from discovery to preclinical testing, a process that traditionally spans several years.

The startup is not only focusing on the technological aspects of drug discovery but is also committed to developing its own pipeline of drug candidates. Currently, Aqemia has three cancer-targeting drug candidates in preclinical testing stages, achieved in less than two years. This marks a significant acceleration compared to the industry average of five to six years for discovery and preclinical phases.

Aqemia's AI model is trained on the physical laws that govern molecular structures in nature, enabling it to "invent" potential drug molecules. The quantum-inspired algorithms then simulate the behavior of these molecules, identifying those with the most promise for further development. This iterative process enhances the efficiency and specificity of the drug candidates produced.

The company's recent partnership with pharmaceutical giants, including a $140 million agreement with Sanofi and a collaboration with Servier, highlight the industry's growing interest in AI's potential to streamline drug discovery. These partnerships focus on identifying molecules for diseases of interest, demonstrating the applicability of Aqemia's technology across various therapeutic areas.

READ MORE: 12 Companies Using Quantum Theory To Accelerate Drug Discovery (Updated)

With the new funding, Aqemia plans to expand its team and accelerate the development of its proprietary drugs, focusing on immunology, inflammation, and central nervous system disorders. The anticipated clinical trials in 2025 will be a crucial test for the company's technology, aiming to demonstrate the efficacy and efficiency of AI-designed drug candidates.

Aqemia

Topics: Startups & Deals   

Share:   Share in LinkedIn  Share in Bluesky  Share in Reddit  Share in Hacker News  Share in X  Share in Facebook  Send by email
#advertisement
ThermoFisher Scientific: Integrated genetic technologies for cell therapy development
#advertisement
Webinar: AI in Clinical Trials

BiopharmaTrend.com

Where Tech Meets Bio
mail  Newsletter
in  LinkedIn
x  X
gnews  Google News
rss  RSS Feed

About


  • What we do
  • Citations and Press Coverage
  • Terms of Use
  • Privacy Policy
  • Disclaimer

We Offer


  • Premium Content
  • BioTech Scout
  • Interviews
  • Partner Events
  • Case Studies

Opportunities


  • Membership
  • Advertise
  • Submit Company
  • Write for Us
  • Contact Us

© BPT Analytics LTD 2025
We use cookies to personalise content and to analyse our traffic. You consent to our cookies if you continue to use our website. Read more details in our cookies policy.